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Abstract
The heart is one of the most demanding organs of the human body. The high nutrient
and oxygen demands need to  be  met  through an adequate  vascularization of  the
myocardium. In fact, the myocardium vascular supply is achieved through an extensive
vascular network that includes larger arteries, also known as coronary arteries, smaller
arteries (arterioles) and capillaries. This set of arterioles and capillaries is known as
microcirculation. Coronary artery disease is usually associated with larger epicardial
coronary arteries. However, several studies have shown an important role of coronary
microvascular dysfunction. This review aimed to explore the (a) morphology, with
particular interest on the anatomical and histological aspects; (b) physiology, providing
an  insight  on  the  several  endothelium-dependent  and  endothelium-independent
regulatory mechanisms; and (c) pathophysiology of the cardiac microcirculation, with
a special focus on the changes in the regulatory mechanisms, on the atherogenesis and
on the correlation to the systemic cardiovascular disease.
Keywords: coronary microcirculation, coronary microvascular morphology, coronary
microvascular physiology, microcirculation regulatory mechanisms, coronary micro-
vascular dysfunction, coronary microvascular pathology
1. Introduction
The heart is one of the most demanding organs of the human body as it presents high demands
for nutrients and oxygen. These demands are physiologically met through an extensive and
unique vascular network, which is usually known as coronary circulation. The coronary circulation
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includes larger arteries, also known as coronary arteries, smaller vessels (with a diameter below
100 μm), such as arterioles, capillaries and venules, that together form the coronary microcir-
culation and larger epicardial veins [1].
Historically, the large epicardial arteries were considered the coronary circulation. Nowadays,
the scientific reports suggest the coronary circulation is characterized by an extreme complex-
ity in terms of morphology but also physiology. Moreover, the theory that the coronary
circulation involves the larger epicardial arteries is no longer acceptable given the extensive
vascular network present in the myocardium.
Coronary artery disease (CAD) is usually associated with larger epicardial coronary arteries.
However, previous studies have shown an important link between microcirculatory dysfunc-
tion and cardiovascular disease. In fact, pathological changes in smaller vessels have been
detected prior to clinical manifestations of cardiovascular disease [1]. Moreover, microcircu-
latory dysfunction may even be a risk indicator for metabolic syndrome and associated
cardiovascular disease [1, 2].
This review aimed to explore the (a) morphology, with particular interest on the anatomical
and histological aspects; (b) physiology, providing an insight on the several endothelium-
dependent and endothelium-independent regulatory mechanisms; and (c) pathophysiology
of the cardiac microcirculation, with a special focus on the changes in the regulatory mecha-
nisms, on the atherogenesis and on the correlation to the systemic cardiovascular disease.
2. Morphology and basic function
Based on the morphology and function, the coronary circulation involves several types of
vessels as follows (from the larger arteries to the largest veins): epicardial arteries or coronary
arteries, small arteries or intramural arteries, arterioles, capillaries, venules and epicardial
veins. These vessels may be grouped according to their size into (a) coronary macrocirculation,
referring to vessels with diameter higher than 100 μm (which includes the coronary arteries,
the intramural arteries and the epicardial veins) and (b) coronary microcirculation, for vessels
with a diameter lower than 100 μm, where the arterioles, capillaries and venules may be
included.
2.1. Arterioles
The arterioles are smaller arteries that originate from the intramural arteries and run parallel
to the myocardial fibres [3–5]. These vessels are characterized by a marked decrease in blood
pressure, contributing to the blood flow resistance, along their length and by an increasing
responsiveness to metabolites, for example hydrogen peroxide, adenosine, among others [3,
4, 6]. Therefore, arterioles represent the main metabolic regulation component of the myocar-
dial blood flow and aim at controlling the blood flow to the capillary network [3, 4, 7].
The anatomy of these vessels varies along their length: the proximal and middle portions tend
to present similar characteristics to the larger arteries, although with a thick tunica media
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[several layers of vascular smooth muscle cells (VSMCs)], while the distal portions, also termed
terminal or precapillary arterioles, may present a thinner tunica media (one to two layers of
VSMCs) or not even present any VSMC layer, which is replaced by small unique cells that will
be explored in the following subsection, the pericytes (Figure 1) [8]. Moreover, the internal
elastic membrane, in the tunica intima, may not be present [6]. The tunica adventitia is usually
thinner in these vessels [6].
Figure 1. Vascular network and capillary neurovascular unit. As presented in the figure, the larger arteries (with a
well-defined smooth muscle layer that may vary in size) present morphological differences to the capillaries, which do
not present smooth muscle layer, being substituted by pericytes. The capillary neurovascular unit then includes the
endothelium, basal lamina and pericytes, which are surrounded by neuron terminals. Moreover, the vascular network
also includes other cell types, such as fibroblasts, collateral blood vessels, among others. Adapted from Zhang et al. [9]
and prepared using Servier Medical Art (http://www.servier.com/).
2.2. Capillaries
The connection between the arterial and the venous systems is fundamentally achieved by a
capillary network placed amid the arterioles and the venules (Figure 1).
The capillaries, with a diameter lower than 10 μm (average of 5.7 μm), are microscopic vessels
that present numerous anastomotic loops (connections between the arterial and the venous
systems), playing a crucial role in the exchange of nutrients and oxygen between the blood
and the myocardium [5]. The capillary density may average up to 3500/mm2 in the healthy
myocardium and seems to vary from the subendocardium, which presents a higher oxygen-
transport, to the subepicardium [5, 10, 11].
These vessels present structural differences to other vessels as the wall is essentially composed
of two layers: an inner layer, the endothelium, and its basal lamina (Figure 1) [6]. In the inner
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layer, the endothelial cell junctions may be smaller, forming intercellular clefts, or larger,
creating intercellular gaps.
According to their morphology, capillaries may be classified into three main categories: (a)
continuous capillaries, (b) fenestrated capillaries and (c) discontinuous capillaries [6]. In the
coronary microcirculation, the continuous capillaries are the most prevalent type. These vessels
are commonly found in muscle, lung and central nervous system and are characterized by the
presence of numerous pinocytotic vesicles and the absence of fenestrations [6]. These fenes-
trations, present in the fenestrated capillaries, are microscopic pores (80–100 nm in diameter)
that allow the rapid diffusion of smaller molecules or proteins, which is particularly important
in some tissues, such as the intestine and endocrine glands [6]. The discontinuous capillaries,
also known as sinusoidal capillaries or sinusoids, present a higher diameter than other capillaries
as well as an irregular shape and may be found in the liver, among other tissues [6].
Embedded in the basal membrane of capillaries, between the endothelium and the parenchy-
ma, small contractile cells called pericytes may be found (Figure 1) [12, 13].
Pericytes may vary morphologically and physiologically depending on the vascular bed and
on the position in the vascular bed itself [13]. Nevertheless, they generally extend processes
along and around capillaries [12, 13]. In the central nervous system and kidneys, pericytes play
an important role in angiogenesis, regulation of the endothelium, among other functions [12,
13]. These cells seem to be particularly relevant in the central nervous system where the
regional blood flow regulation is of crucial importance [13]. These pericytes may also present
contractile properties [12, 13]. Several proteins have been suggested to confer contractility to
pericytes, such as α-smooth muscle actin and tropomyosin [13]. However, previous studies
suggest that the contractile mechanisms differ from the VSMCs [13].
Although the role of pericytes in coronary physiology is not yet fully understood, the high
number of these cells in cardiac capillaries and the similar characteristics to the central nervous
system pericytes indicates these cells may play an important role in the regulation of the vessel
diameter as well as permeability [12].
In the capillary network, other structures may be found such as capillary sinuses, which consist
of reservoir-like spaces that could behave as micropumps [8].
2.3. Venules
After the exchange of nutrients and oxygen at the capillary level, the deoxygenated blood,
containing metabolic products, proceeds to the venules, which present numerous intercom-
munications, through confluence of capillaries and postcapillary vessels [5]. Although the
coronary circulation has been extensively studied over the years, little is known about the
intramural venous system. Nevertheless, previous studies have suggested a larger venous
network comparatively to the arterial network in the myocardium [5]. In fact, the existence of
two veins per artery has been suggested [5].
The venules usually present a diameter ranging from 10 to 50 μm and similar anatomical
characteristics to the arterioles [8]. The proximal venules, that is postcapillary venules, usually
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exhibit only two layers: an inner layer, the endothelium and an outer layer, the basal membrane
[6, 8]. The endothelium of the venules seems to be highly responsive to vasoactive agents,
namely histamine and 5-hydroxytryptamine, commonly known as serotonin [6]. As well as in
terminal arterioles and capillaries, pericytes may also be found in the venular wall in a partic-
ularly higher extent than in arterioles or capillaries [6, 8].
The distal venules are morphologically different relatively to the postcapillary venules, as they
may present a thin tunica media (one to two layers of VSMCs) and a thin tunica adventitia on
the outer side of the vessel [6]. The absence of pericytes is a key characteristic of these distal
venules [6]. These venules initially course parallel to the muscle fibres, accompanying the
arterioles and capillaries, then changing their position and configuration to meet the larger
coronary veins [5].
2.4. Special circulatory considerations
2.4.1. Arteriovenous shunts
In healthy conditions, the myocardial blood supply is fundamentally provided through the
normal coronary circulation. However, in the presence of cardiac disease, such as chronic
cardiac disease or regional ischemic injuries, the myocardial perfusion may be compromised
[4, 5]. Compensatory circulatory communications named arteriovenous anastomoses or shunts
seem to play a key role in the preservation of the myocardial perfusion in these situations [4,
5, 14]. This collateral circulation links directly the arteries or arterioles to the veins or venules,
bypassing the capillary bed [14]. The arteriole of these shunts frequently presents morpho-
logical particularities: a thicker tunica media with a higher content in VSMCs, a more developed
tunica adventitia, forming a capsule of connective tissue, abundant innervation and are frequently
coiled [6].
2.4.2. Heart chamber-coronary circulation direct communication
The direct communication between the heart chamber and the coronary circulation is generally
referred to Thebesian vessels [5]. These vessels were first described by Thebesius in 1708 [15]
and involve the communication between the heart chamber and the capillaries and venules,
referring to a venular connection [5, 16, 17]. These veins usually present a diameter of 200–
400 μm and are more frequent in the right ventricle [5]. This type of chamber-vessel commu-
nication was later studied by Wearn et al. [18] who further described and defined this and other
types of vessels, namely the arteriosinusoidal vessels and the arterioluminal vessels [5, 16,
18]. The arteriosinusoidal vessels provide a communication between a heart chamber and a
myocardial sinusoid and are irregularly shaped short branches (diameter from 50 to 350 μm)
composed of just an endothelial layer [5, 18]. The arterioluminal vessels are smaller vessels
(diameter from 40 to 200 μm) that provide a direct communication to a heart chamber (more
frequently the left ventricle), presenting a morphology similar to arterioles [5, 18]. Although
previous studies have demonstrated the presence of these special vessels, their clinical
significance is still debatable [5].





The physiologic behaviour of the coronary circulation is inherently linked to a balance between
the blood supply and the metabolic demand of the heart [19]. Furthermore, the physiological
responses in the microcirculation seem to depend on the vessel size and type and appear to
vary within the microcirculation itself and from those in the macrocirculation [19–21].
Physiologically, the coronary microcirculation is able to respond to a wide range of stimuli,
such as growth and physical exercise, through adaptive processes, essential to the maintenance
of its physiology [19]. In fact, vessels present a high adaptation ability and may undergo both
acute and chronic adjustments. The acute adjustments involve changes in the vascular smooth
muscle tone, while the chronic adjustments involve wall structure changes [19].
The vascular tone is defined as the ratio between baseline and maximal vessel diameter and is
determined by the vascular smooth muscle function [19]. In turn, this is regulated by several
mechanisms, such as (a) the myogenic tone, which is an intrinsic property of the VSMC, (b)
the metabolic control exerted by adjacent cells, (c) the endothelial function responding to
changes in the shear stress and (d) autonomic innervation and circulating factors, such as
hormones [19].
3.2. Myogenic tone
The myogenic tone is produced by the response of the VSMCs to changes in transmural pressure
that leads to stretching of the vessel wall [19, 22, 23]. This relation seems to be linear, that is
increasing transmural pressure leads to higher vasoconstriction (reduction in the lumen
diameter) [19]. The mechanism underlying this response appears to involve the opening of ion
channels, namely nonspecific cation channels, with an increase in intracellular sodium and
calcium and consequently the depolarization of the VSMCs [19]. Several receptors have been
implicated in the myogenic response, such as (a) integrins [24], (b) transient-receptor potential
channels (TRPs) [25, 26] and (c) G protein-coupled receptors [27].
3.3. Metabolic regulation
The coronary blood flow is intrinsically linked with metabolic demands of the myocardium,
namely of oxygen. At rest, the myocardial oxygen extraction averages 60–70%, which leads to
the coronary venous pO2 of about 20 mmHg [28]. During physical exercise, several mechanisms
of adaptation are triggered in the myocardium, pO2 seems to be kept constant, which highlights
the role of several pathways, namely the myocardial aerobic metabolism [28]. This energy
production is generally dependent on mitochondrial oxidative phosphorylation pathways
[19]. Among several metabolites produced in these intracellular pathways, carbon dioxide
(CO2) and reactive oxygen species (ROS) seem to play an important role in physiological
conditions [19, 28].
As previously mentioned, CO2 production is linked to metabolic demands and therefore
dependent on the myocardium oxygen consumption [19, 28]. This metabolite results from two
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main metabolic pathways: (a) the pyruvate dehydrogenase reaction and (b) the citric acid
cycle [28]. The pyruvate dehydrogenase reaction converts pyruvate into acetyl-CoA, which is
a substrate for the production of citrate, according to the following reaction:
Pyruvate dehydrogenase
2Pyruvate CoA NAD Acetyl CoA CO NADH H+ ++ + ¾¾¾¾¾¾¾® - + + + (1)
After the conversion of oxaloacetate into citrate, the citric acid cycle involves several reactions
in chain. Some of them also involve the production of CO2, such as the production of α-
ketoglutarate (reaction 2) and succinyl-CoA (reaction 3).
Isocitrate dehydrogenase 2D - Isocotrate + NAD Ketoglutarate+CO NADH+Ha+ +¾¾¾¾¾¾¾¾¾® - + (2)
α Ketoglutarate dehydrogenase
2α Ketoglutarate CoA NAD Succinyl CoA CO NADH H-+ +- + + ¾¾¾¾¾¾¾¾¾® - + + + (3)
The increased production of CO2 may also induce a decrease in pH due to the increase in proton
concentration, as presented in the following reaction:
2 2 3CO  H O  H  HCO+ -+ « + (4)
This change in pH seems to promote the coronary vasodilation [28–30].
As can be seen in Figure 2, the metabolic production of ROS also plays an important role in
the metabolic regulation of the coronary blood flow involving a feedforward mechanism [19,
28]. Among the several ROS, hydrogen peroxide (H2O2) seems to be one of the most important
metabolites being considered a feedforward vasodilator [31]. H2O2 results from the conversion
of superoxide anions (O2⋅−) by the superoxide dismutase (SOD) [28]. In turn, the superoxide
anions result from the reduction in O2 by electrons released from mitochondrial complexes (I
and III) [28]. This pathway may be stimulated by shear stress in human coronary resistance
arteries [32].
The vasodilator properties of H2O2 have long been studied, but the precise underlying
mechanisms are not yet fully established [28]. Previous studies suggested H2O2 behaves as an
endothelium-derived hyperpolarizing factor (EDHF) [34, 35], as described in the following
subsection. However, other previous studies suggested the mechanism may involve the
stimulation of the nitric oxide (NO) production or be mediated by the guanylyl cyclase in
human coronary arterioles [36]. These pathways will be further discussed in the following
subsections.
Other studies have suggested additional mechanisms involved in the metabolic regulation
exerted by H2O2 on the coronary blood flow. The involvement of oxidation of thiol groups as
a pathway of coronary metabolic dilation in isolated coronary arterioles has been previously
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proposed [37]. The thiol groups are involved in many pathophysiological mechanisms and
play a key role in the biological protection against oxidative injuries [38, 39]. This oxidation
process promotes modifications in the protein conformation and includes the conversion of
protein-bound thiols (-SH) into sulfenic (SO−, reaction 5), sulphinic (SOO−) and sulphonic
(SOOO−) acids as well as disulphide bridges (S-S, reaction 6) [37, 39].
Figure 2. Feedforward reactive oxygen species-dependent metabolic regulation of coronary blood flow. The increased
metabolic demands of the myocardium trigger an increase in mitochondrial metabolism and flux, through the electron
transport chain (ETC), increasing the production of O2⋅− and subsequently of H2O2 by manganese SOD (MnSOD).
H2O2 then diffuses to the VSMC and activates voltage-dependent K+ (KV) channels promoting the hyperpolarization of
the VSMCs and thus the vasodilation in the coronary microcirculation. Adapted from Muller-Delp [33] and prepared
using Servier Medical Art (http://www.servier.com/).
2 2 2R SH H O R SOH H O- + ® - + (5)
2R SOH RSH R SS R H O- + ® - - + (6)
Furthermore, these modifications in the redox state of the cell may also affect the hyperpola-
rization mediated by thiol-dependent voltage-dependent K+ (KV) channels, which will be
further explored in the following subsection [40].
Other metabolic vasodilators may also be involved, such as adenosine (which concentration
is dependent on the metabolism) and potassium ions, which will be explored further below.
3.4. Endothelial function
The endothelial function plays a crucial role in the vascular physiology, especially in the
regulation of the vascular tone. The endothelium is responsible for the production of a number
of different vasoactive substances, such as: (a) endothelium-derived contracting factors (EDCFs),
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such as endothelin, prostanoids and 20-hydroxyeicosatetraenoic acid (20-HETE) and (b)
endothelium-derived relaxing factors (EDRFs), such as NO, prostaglandins (e.g. prostacyclin) and
EDHFs, for example H2O2 and epoxyeicosatrienoic acids (EETs) [35, 41–47].
Vasoconstrictors. The stimulation of receptors in the endothelial cell membrane may trigger the
production of several EDCFs, namely prostanoids and endothelin, particularly endothelin-1,
among others (Figure 3) [35, 41]. The prostanoids are vasoactive substances that result from the
arachidonic acid pathway. Following the stimulation of specific membrane receptors, such as
muscarinic receptors for acetylcholine and purinergic (P2Y) receptors for adenosine triphos-
phate (ATP), the increase in intracellular Ca2+ promotes the production of arachidonic acid
from membrane phospholipids by phospholipase A2 [41]. The arachidonic acid is then
converted by the endothelial cyclooxygenase-1 (COX-1) to endoperoxides and ultimately to
prostanoids, namely thromboxane A2 (TXA2) and prostaglandins, such as prostacyclin (PGI2)
[41]. Additionally, the COX-1 activity might also promote the production of ROS [41]. Those
vasoactive substances (i.e. TXA2 and prostaglandins) may then diffuse to the smooth muscle
layer where they activate thromboxane-prostanoid (TP) receptors, promoting the contraction
of the VSMCs [41].
Figure 3. Multitude of pathways involved in the endothelium-dependent contraction. Abbreviations: 5-HT, 5-hydro-
tryptamine; ACE, angiotensin-converting enzyme; ACh, acetylcholine; ADP, adenosine diphosphate; AT-I, angiotensin-
I; AT1, angiotensin receptor; AT-II, angiotensin-II; ATG, angiotensinogen; BDK, bradykinin; COX, cyclooxygenases;
ECE, endothelin-converting enzyme; ET-1, endothelin-1; ETA, endothelin receptor A; ETB, endothelin receptor B; NO,
nitric oxide; eNOS, endothelial nitric oxide synthase; NOX, NADPH oxidase; PGs, prostaglandins; PLA2, phospholi-
pase A2; ROS, reactive oxygen species; TGFβ1, transforming growth factor; Thr, thrombin; TP, thromboxane-prostanoid
receptor; TXA2, thromboxane A2; VSMC, vascular smooth muscle cell; XO, xanthine oxidase. Adapted from Virdis et al.
[49] and prepared using Servier Medical Art (http://www.servier.com/).
Endothelin (ET) is considered a major vasoactive substance in the EDCF family and a major
vascular function regulator. In fact, this term refers to a group of peptides synthesized by the
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endothelin-converting enzyme (ECE) that may mediate vasoconstriction through the stimu-
lation of receptors, namely ETA and ETB receptors, in the VSMC membrane [48, 49]. Among
the several peptides, ET-1 is the most known, and its vasoactive properties have been exten-
sively researched. This peptide promotes a long-lasting vasoconstriction essential to the vessel
tone control in coronary arterioles, as reduction ET-1 induces an elevation of coronary blood
flow in increased demand situations, that is increased metabolism [50, 51].
20-HETE is a metabolite that results from the conversion of arachidonic acid by the 4A and 4F
families of cytochrome P450 mono-oxygenases (CYP), particularly in the VSMCs but also in
the endothelial cells [35]. This metabolite seems to play an important role in the regulation of
the vascular tone, behaving as a potent endogenous vasoconstrictor in several vascular tissues,
namely in the brain and in the heart [35, 52].
Vasodilators. NO is the most researched EDRF worldwide and is produced in the endothelial
cells by the endothelial nitric oxide synthase (eNOS). This constitutive enzyme converts L-
arginine to L-citrulline and requires several cofactors, such as calcium, calmodulin, 3,4-
tetrahydrobiopterin (BH4) and nicotinamide adenine dinucleotide phosphate (NADPH) [53].
The NO-mediated vasodilation primarily involves the conversion of guanosine triphosphate
(GTP) to cGMP by soluble guanylyl cyclase (solGC) [34]. However, other mechanisms may
also be involved in the NO-mediated vasodilation, namely the hyperpolarization of the
VSMCs [34, 54], which will be further explored below. The production of NO may be regulated
by several mechanisms, which have been previously explored and published [55]. In addition
to the stimulation of receptors on the endothelial cell membrane, the eNOS-mediated produc-
tion of NO may also be stimulated by shear forces exerted by the blood flow on the vessel wall,
as explored further below.
Figure 4. Pathways involved in the endothelium-dependent and endothelium-independent relaxation of the VSMC.
Stimulation of the endothelial cells by acetylcholine (ACh) or other agents (e.g. bradykinin and shear stress) results in
the formation and release of an EDRF identified as nitric oxide (NO). Substances such as adenosine, nitroprusside
(NP), H+, CO2 and K+ can be produced in the parenchymal tissue and elicit vasodilation by direct action on vascular
smooth muscle. Adapted from Koeppen et al. [58] and prepared using Servier Medical Art (http://www.servier.com/).
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Although NO is considered the major pathway of endothelium-mediated vasodilation in the
systemic circulation, multiple pathways may be involved in this physiological response, such
as the prostaglandins-induced vasodilation (Figure 4). The prostaglandins are constitutively
produced by cyclooxygenases (COX) [34]. The main substrate of these enzymes is arachidonic
acid, which is converted from diacylglycerol or phospholipids, respectively, by phospholi-
pase A2 and phospholipase C [34]. Several prostaglandins are produced by COX, although the
main vasoactive prostaglandin produced in the endothelium is PGI2 [35, 56, 57]. Similarly to
NO, PGI2 may diffuse from the endothelial cells to the VSMCs where they activate their (IP)
receptors and trigger the conversion of ATP into cyclic adenosine monophosphate (cAMP) by
adenylyl cyclase (AC) [34, 57]. This activation promotes the hyperpolarization of the VSMCs
and hence the vasodilation [34, 57]. However, these prostaglandins, namely PGI2, may also
elicit vasoconstriction in disease, as previously discussed [35, 41].
Several vasoactive substances have been included in the EDHFs family, such as H2O2, carbon
dioxide (CO2), hydrogen sulphide (H2S), C-natriuretic peptide (CNP), EETs, potassium ion (K
+), among others [34, 35, 54, 59]. Previous studies suggested these factors play a key role in the
VSMC hyperpolarization in smaller vessels rather than in larger ones [19, 34].
Figure 5. Hyperpolarization of the VSMC. Abbreviations: ACh, acetylcholine; BK, bradykinin; BKCa, large conductance
Ca2+-activated K+ channels; CaV, voltage-activated Ca2+ channels; Cx, connexin; EC, endothelial cell; eNOS, endothelial
nitric oxide synthase; IKCa, intermediate conductance Ca2+-activated K+ channels; KIR, inwardly rectifying K+ channels;
NO, nitric oxide; PE, phenylephrine; RyR, ryanodine receptor; SKCa, small conductance Ca2+-activated K+ channels; SP,
substance P, TRPC1, transient receptor potential canonical channel 1; TRPV4, transient receptor potential vanilloid
channel 4; VSMC, vascular smooth muscle cell. Adapted from Félétou et al. [35] and prepared using Servier Medical
Art (http://www.servier.com/).
The hyperpolarization of the VSMC may involve several ionic channels, such as the voltage-
activated Ca2+ (CaV) channels, which regulate the intracellular Ca2+ concentration, the KV
channels and the Ca2+-activated K+ (KCa) channels [35, 40]. The KCa channels may be subdivided
into small (SKCa or KCa 2.3 isoform), intermediate (IKCa or KCa 3.1 isoform) and large (BKCa)
conductance Ca2+-activated K+ channels, which are located in specific cellular and subcellu-
lar sites [35]. The hyperpolarization of the VSMCs may be triggered directly, through receptors
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on the VSMC membrane, or indirectly, through the hyperpolarization of the endothelial cells
[35].
As can be seen in Figure 5, the direct hyperpolarization may be promoted through the stimulation
of BKCa channels on discrete locations of the VSMC layer, that is smooth muscle plasmerosome,
associated with the TRP canonical channel 1 (TRPC1) and the TRP vanilloid channel 4 (TRPV4).
These signal complexes promote (a) the influx of Ca2+, which is then stored through ryanodine
receptor (RyR) on the endoplasmic reticulum and (b) the efflux of K+, contributing to the
formation of a potassium cloud in the intercellular space, which functions as a negative-
feedback mechanism. This ionic cloud may activate inwardly rectifying K+ (KIR) channels and
Na+/K+-ATPase promoting the influx of K+ to the VSMC, thus leading to the hyperpolarization
and vasodilation. This hyperpolarization also inhibits the Ca2+ influx through CaV channels
that may be stimulated by the binding of noradrenaline or phenylephrine to the adrenergic
receptors on the membrane of VSMCs. The stimulation of these receptors leads to the increase
in the intracellular Ca2+ concentration triggering the depolarization of the VSMC. Furthermore,
this increase in intracellular Ca2+ may subsequently activate KV and BKCa channels, which then
promote the efflux of K+ ions to the intercellular space, thus controlling the ionic balance and
contributing to the formation of the potassium cloud [35, 57].
Moreover, the VSMCs may be indirectly hyperpolarized through the hyperpolarization of the
endothelial cells [35]. Following activation of endothelial receptors and action of shear stress,
the increased intracellular calcium in the endothelial cell triggers the opening of SKCa (located
at the homocellular endothelial gap junctions and caveolin-rich domains) and IKCa channels
(preferentially located at the myoendothelial gap junctions or MEJ) leading to K+ efflux and
consequently to the hyperpolarization of the endothelial cell [35]. In turn, this may ultimately
lead to the hyperpolarization of the VSMCs by direct electric coupling through MEJs, which
consist of a cell-cell contact resulting from the projection of an endothelial cell or a VSMC
through the internal elastic membrane (Figure 5) [35, 60]. These contacts are essentially
established through connexins (Cx), namely Cx40 and Cx37 [35, 61]. Particularly, at the level
of the MEJs, the IKCa channels may be activated directly or through the generation of Ca2+
pulsars, contributing further to the potassium cloud in the intercellular space, eventually
promoting the activation of KIR channels and Na+/K+-ATPase involved in the hyperpolarization
of the VSMCs. The influx of Ca2+ from the intercellular space to the VSMC, through CaV
channels may be detected by Ca2+-sensing receptors (CaSR), which may activate IK1 gene,
involved in the hyperpolarization of the VSMC [35, 57].
Besides the hyperpolarization of the VSMCs, the EDHFs, particularly H2O2, may also promote
vasodilation through other mechanisms, namely by stimulating the production of prostaglan-
din E2 in the endothelial cell, thus promoting the endothelium-dependent vasodilation [62].
The relative importance of each pathway is still unestablished, but it has been proposed to
depend for example on the activation state of the VSMCs, the density of MEJs and the
expression of KIR and Na+/K+-ATPase [57].
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3.4.1. Shear stress
As previously mentioned, in addition to the stimulation of receptors on the endothelial cell
membrane, other factors may modulate the endothelial function, namely the forces exerted by
the blood flow on the vessel wall. There are two major forces: (a) one perpendicular to the wall
and (b) another parallel to the wall, known as wall shear stress that results from the friction of
blood flow on the endothelial cells [63]. These shear forces trigger several pathways, such as
(a) production, release and binding of bradykinin to endothelial cell membrane receptors and
(b) bradykinin-independent pathways, namely the activation of the Akt phosphorylation
pathway and the ROS-mediated hyperpolarization of the VSMC. The production and release
of bradykinin, which may bind to its Gq-coupled endothelial receptors, increases the activity of
eNOS thus promoting the synthesis of NO [64]. The activation of the Akt phosphorylation
pathway also promotes the production of NO by eNOS [64, 65]. In human coronary arterioles,
the shear forces exerted on the vessel wall may also promote the ROS-mediated hyperpolarization
of the VSMC through two main mechanisms: one involving the EETs and other involving the
direct stimulation of ROS production (Figure 6). First, the shear stress may induce the
production of EETs by triggering the cleavage of arachidonic acid from the cellular membrane
by phospholipases. The arachidonic acid then works as a substrate to CYP for the production
of EETs, which may activate the TRPV4 channels promoting an increase in intracellular Ca2+,
thus stimulating the mitochondrial production of O2⋅−. The production of ROS may also result
Figure 6. Flow-mediated dilation in the human coronary arterioles. Abbreviations: AA, arachidonic acid; BKCa, large
conductance Ca2+-activated K+ channels; cGMP, cyclic guanosine monophosphate; CuZnSOD, copper-zinc superoxide
dismutase; CYP, cytochrome P450; CYS 42, cysteine residue; EETs, epoxyeicosatrienoic acids; GC, guanylyl cyclase;
GTP; guanosine triphosphate; H2O2, hydrogen peroxide; KCa, Ca2+-activated K+ channels; MnSOD, manganese superox-
ide dismutase; NADPH, nicotinamide adenine dinucleotide phosphate; NOX, NADPH oxidase; O2⋅−, superoxide
anion; PKG1α, protein kinase G 1α; PLA2, phospholipase A2; PLs, phospholipids; TRPV4, transient receptor potential
vanilloid channel 4. Adapted from Durand et al. [34] and prepared using Servier Medical Art (http://www.servi-
er.com/).
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from the direct stimulation of TRPV4 channels and NADPH oxidases. The O2⋅− produced
through both these mechanisms is then dismutated to H2O2, which diffuses to the VSMCs to
oxidize cysteine residues of protein kinase G 1α (PKG1α), activating this enzyme. The activation
of this enzyme promotes the opening of BKCa channels and the hyperpolarization of the VSMCs
resulting in vasodilation of coronary arterioles [32, 34, 66, 67].
Previous studies showed the sensitivity to these pathways of vasodilation increases with
decreasing vessel diameter thus assuming a particularly important role in the coronary
microcirculation [19]. Previous studies have also suggested the relative weight of these
pathways changes from childhood to adulthood and between healthy and pathological
conditions. In a preliminary study with human-isolated arterioles, Zinkevich et al. [68]
proposed the flow-mediated dilation (FMD) in infants was exclusively COX-dependent, that
is mediated by prostaglandins, while in adulthood the main pathway involved the NO.
However, in the presence of coronary artery disease (CAD), both these mechanisms seem to
remain as secondary pathways as the EDHF-mediated vasodilation (especially by H2O2) gains
importance, serving as backup mechanisms in disease [66]. In fact, low response to shear forces
and high mechanical stress seem to predispose to vascular dysfunction and disease [63].
3.4.2. Endothelium-cardiomyocyte interaction
The heart is a highly organized organ where several cells may be found, namely endothelial
cells and cardiomyocytes. Therefore, the physiological mechanisms depend on the communi-
cation between the several types of cells. Until today, many endothelial-derived cardio-active
factors have been identified and characterized (Figure 7). The cardiac modulator effects of
some of these factors, such as NO, PGI2, ET-1 and neuregulin-1 (NRG-1), have been previously
acknowledged. Other factors, namely Dickkopf-3 (DKK3), periostin, thrombospondin-1
(TSP-1), follistatin (FST), apelin and connective tissue growth factor (CTGF), also appear to
Figure 7. Communication between endothelial cells and cardiomyocytes. Abbreviations: CTGF, connective tissue
growth factor; DKK3, Dickkopf-3; ET-1, endothelin; FST, follistatin; NO, nitric oxide; NRG-1, neuregulin-1; PGI-2, pros-
tacyclin; TSP-1, thrombospondin. Adapted from Lim et al. [69].
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modulate the cardiomyocyte function, though with little evidence so far. These cardio-active
factors seem to be interdependent (additive, synergistic or inhibitory) as their modulator
effects may be exerted on the same target cell [69].
3.5. Autonomic innervation and circulating factors
The previously explored pathways are nowadays considered the major pathways of regulation
of the vessel tone. However, other mechanisms may also come into play, such as the autonomic
nervous system and circulating factors.
The innervation of the coronary circulation by the sympathetic and the parasympathetic
divisions of the autonomic nervous system have been previously shown [70]. The endothelial
production of vasoactive substances, namely NO, may be influenced by the stimulation of
specific receptors in the endothelial cell membrane, such as muscarinic receptors for acetyl-
choline [41, 70]. Furthermore, the coronary circulation may also be regulated through adre-
nergic receptors (i.e. α- and β-adrenergic receptors) in both the endothelial cell and the VSMC
membranes [70]. In general, the stimulation of the α-adrenergic stimulation seems to induce
vasoconstriction, with the exception for the α2 receptors which seem to elicit vasodilation.
Moreover, the stimulation of β-adrenergic receptors generally induces vasodilation with β2
receptors being the main population in the coronary microcirculation [19, 70, 71]. This
autonomic innervation provides a mechanism for vessel tone regulation, particularly impor-
tant during exercise. However, the role of the parasympathetic innervation remains debatable
in the human coronary microcirculation [70].
Moreover, several circulating factors may also modulate the coronary blood flow through the
regulation of the vessel tone, such as angiotensin II and other hormones (e.g. cortisol and
tiroxine, among others), adipokines (particularly adiponectin) and growth factors among
many others [19, 72].
4. Microcirculation pathophysiology
As previously discussed, the coronary microcirculation plays a key role in the myocardial
perfusion. Therefore, the presence of functional and/or structural abnormalities of this
circulatory pathway may impair the myocardial perfusion and be involved alone as the main
mechanism of myocardial ischaemia. These abnormalities are normally designated as coronary
microvascular dysfunction (CMD) [3]. The CMD may be assessed by several methods, though
one of the most used methods is through the determination of the coronary flow reserve (CFR),
which represents an integrated measure of coronary blood flow in both the macro- and
microcirculation. The CFR involves the maximal vasodilation of a vessel in response to an
endothelium-independent vasodilator, such as adenosine, thus reflecting the ratio of hyper-
aemic to baseline blood flow. This ratio may be measured through several methods, namely
echocardiography and positron emission tomography (PET) [3].
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CMD type Clinical setting Pathogenic mechanisms
In the absence of myocardial disease or
obstructive CAD





















Abbreviations: AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; DCM, dilated
cardiomyopathy; HCM, hypertrophic cardiomyopathy; PCI, percutaneous coronary intervention; VSMC, vascular
smooth muscle cell. Adapted from Crea et al. [20].
Table 1. Classification of CMD according to the involvement of pathogenic mechanisms and the clinical setting.
CMD may present several pathogenic underlying mechanisms, depending on the source of
the abnormality, namely structural and functional (Table 1), which will be discussed in this
section. According to the underlying clinical setting, the CMD may also be classified into four
types: type 1, in the absence of cardiomyopathies or obstructive CAD; type 2, in the presence
of cardiomyopathies; type 3, in the presence of CAD; and type 4, iatrogenic [3, 20, 73, 74].
4.1. Functional abnormalities
The most common functional abnormalities are the dysfunction of the endothelial cells and/or the
VSMCs, involving cardiovascular risk factors or cardiomyopathies, and the autonomic nervous
system dysfunction, secondary to coronary reperfusion procedures.
4.1.1. Endothelial and/or VSMC dysfunction
As presented in Table 1, the traditional cardiovascular risk factors (i.e. ageing, gender, obesity,
smoking, hypertension, dyslipidaemia and diabetes) may impair the endothelial function by
several mechanisms, namely increased production of EDCFs and/or decreased production of
EDRFs [3, 73]. Furthermore, this impairment may also contribute to the dysfunction of the
VSMCs, which may also result from structural changes, derived from cardiomyopathies or
arterial hypertension, described further below.
Ageing is considered as one of the major cardiovascular risk factors that may influence the
endothelial function. This influence seems to primarily involve both functional and structural
changes, which will be discussed further below [42, 75]. Several mechanisms have been
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identified to mediate these changes and have been previously reviewed [55, 64, 76, 77]. In fact,
the imbalance between vasoconstriction and vasodilation seems to be a key mechanism
underlying ageing-induced vascular dysfunction.
Gender-associated differences related to hormones (i.e. oestrogens) have been previously
described for the vascular reactivity in several vascular beds [42, 65]. The stimulation of G
protein-coupled receptors by these hormones seems to promote an increased production of
EDRFs, especially NO, which could elucidate the lower incidence of coronary disease and
atherosclerosis in premenopausal women compared to men of the same age and postmeno-
pausal women. In fact, impaired expression of eNOS was previously reported in postmeno-
pausal women and suggested as a gender-specific risk factor in coronary surgery [78].
Moreover, Muir et al. [79] also showed differences in the endothelium-dependent vasodilation
between males and females. In the coronary circulation, oestrogens seem to promote a
decreased vascular tone, which promotes a reduced blood flow resistance and thus a higher
coronary blood flow [80].
Obesity has also been considered an important cardiovascular risk factor; thus, a healthy diet
and the regular practice of exercise have been proposed as important preventive measures.
The influence of obesity in the vasoreactivity involves several mechanisms, namely an
impaired regulation of vascular tone, a systemic chronic inflammation, induced by adipokines,
which are involved in CMD, an altered lipidic profile (i.e. dyslipidaemia) and increased
incidence of atherosclerosis and vascular oxidative stress [55, 80–82].
Cigarette smoking has been widely recognized as a major cardiovascular risk factor that induces
endothelial dysfunction. In the peripheral circulation, this effect primarily involves the
decreased production of EDRFs, namely NO, mainly through the impairment of eNOS
activity [79, 83]. Interestingly, this downregulation of NO-mediated vasodilation seems to be
exposure-dependent [84]. The ability to induce endothelial dysfunction may also manifest in
the coronary circulation, particularly in long-term smokers, independently of the presence of
atherosclerotic plaques [85]. Moreover, Kaufmann et al. [86] found CMD in asymptomatic
smokers in the absence of CAD. These patients presented a reduction in 21% of the CFR, which
could be restored with the short-term administration of vitamin C. These findings suggested
that the smoking-associated CMD may involve an increase in oxidative stress in the coronary
microcirculation [86].
Similarly to smoking, arterial hypertension is also considered a major cardiovascular risk factor.
Previous studies suggested the increased production of EDCFs as the main mechanism
underlying the hypertension-induced endothelial dysfunction [41]. This effect is primarily
triggered by an increase in intracellular Ca2+, stimulating a higher production of COX-derived
prostanoids (e.g. TXA2 and PGI2) and ROS, namely O2⋅− [41]. The prostanoids may then diffuse
to the VSMCs activating TP receptors, with subsequent influx of Ca2+, creating the conditions
to a predominant vasoconstriction [41]. The ROS may also influence the vascular function since
they may react with NO, reducing its availability, or even stimulate the influx of Ca2+ [41].
The vascular effects of dyslipidaemia, namely hypercholesterolaemia, are dependent on the
degree of atherogenesis. In fact, the accumulation and oxidation of low-density lipoproteins
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(LDLs) are considered major steps in the development of the chronic inflammatory process
that is atherosclerosis [87]. The accumulation of LDL in the subendothelial matrix depends on
the circulating LDL levels as the LDLs diffuse from the lumen to the vessel wall through
endothelial cell junctions [87]. Once in the subendothelial matrix, the LDLs may undergo
oxidation by reacting with endothelium-derived ROS, producing oxidized LDLs [87]. These
proinflammatory factors may mediate several effects on the vessel wall, mainly the impairment
of NO-mediated vasodilation and the atherogenesis [64]. In fact, oxidized LDLs may (a) trigger
the influx of asymmetric dimethyl-L-arginine (ADMA), which is a competitor substrate for
eNOS, (b) downregulate the NO production through the Rho kinase and protein kinase C
pathways and (c) promote the uncoupling of eNOS by upregulating the NADPH oxidase
production of ROS [64]. Previous studies in the human coronary circulation have revealed a
reduced CFR in asymptomatic patients with hypercholesterolaemia, which seems to be
reversible with a cholesterol-lowering therapy [88–91].
Diabetes is a known cardiovascular risk factor responsible for several effects on the cardiac and
peripheral vascular systems, which intermediate an increased morbidity and mortality [92].
In spite of the array of mechanisms involved, the relation between diabetes and CMD is not
yet fully understood [93]. Previous studies suggested several mechanisms involved in the
diabetes-induced vascular dysfunction, namely (a) impaired production of NO, due to BH4
deficiency, increased arginase activity, increased ADMA influx or downregulation of the Akt
phosphorylation pathway; (b) increased production of EDCFs, namely endothelin; and (c)
other NO-independent mechanisms, such as hyperglycaemia [55]. Chronic hyperglycaemia
has been previously suggested to play a key role in the diabetes-related CMD, as several
mechanisms may be involved [55], namely the endothelial-protein glycation through the
formation of advanced glycation end-products (AGEs) and subsequent stimulation of the
respective receptors (RAGE). In fact, previous studies suggested that diabetic patients (both
type 1 and type 2) present a marked reduction in the endothelium-dependent and endotheli-
um-independent coronary vasodilation [94].
The impairment of the vasodilator response of the coronary microcirculation may also be
present in patients with angina-like chest pain but without evidence of obstructive CAD or
myocardial disease. This situation is usually known as microvascular angina or coronary
syndrome X. The literature seems to be contradictory as some studies suggest no changes in the
coronary blood flow and in the CFR [73], while others showed the presence of CMD through
impairment of the endothelium-dependent and endothelium-independent vasodilation [95],
reduction in the coronary blood flow and CFR [96] and evidence of myocardial ischaemia [97,
98]. However, the precise pathogenic mechanisms involved in these changes are not yet
completely understood as this situation seems to be multifactorial [99].
4.1.2. Autonomic nervous system dysfunction
The autonomic nervous system dysfunction, following acute myocardial infarction (AMI) and/
or coronary reperfusion procedures, may also contribute to the CMD. In fact, increased
coronary vasoconstriction has been previously shown, after AMI and successful percutaneous
Microcirculation Revisited - From Molecules to Clinical Practice32
coronary angioplasty, both at the site of stenosis and distal to it, suggesting abnormal coronary
vasodilator response [73, 100].
After AMI, the CMD may result from autonomic dysfunction and luminal obstruction,
discussed further below. The autonomic dysfunction in the AMI-associated CMD involves
increased sympathetic activation with increased vasoconstriction. These findings were
confirmed by Gregorini et al. [101], who showed this impaired autonomic function might be
reverted with α-blockers, such as phentolamine (nonselective α-blocker) and urapidil (α1-
selective blocker), which may improve the recovery of myocardial perfusion after coronary
stenting in patients with AMI [101–103]. Autonomic dysfunction secondary to percutaneous
coronary angioplasty was also showed by Gregorini et al. [104] who linked the left ventricular
macro- and microcirculatory dysfunction in patients with transient ischaemia. In this study,
phentolamine and urapidil were similarly used to block the α-adrenergic neurotransmission
and propranolol (nonselective β-blocker) and the β-adrenergic neurotransmission, and the
results showed that the increased coronary vasoconstriction, secondary to percutaneous
coronary angioplasty, may be prevented with α-adrenergic receptor antagonists as no effect
was demonstrated for the β-adrenergic blockade. Moreover, this study suggested that CFR
may still be decreased for 7 days to 3 months after the procedure [104]. In a similar study,
Kozàkovà et al. [105] confirmed the potential usefulness of urapidil to improve the left
ventricular function in the angioplasty follow-up. Moreover, persistent yet reversible CMD
after coronary revascularization was also previously showed [106].
4.2. Structural abnormalities
In addition to functional abnormalities, structural abnormalities, namely vascular remodel-
ling, vascular rarefaction, perivascular fibrosis, luminal obstruction and infiltration of the
myocardium and vascular wall, may also contribute to CMD [3, 73].
4.2.1. Vascular wall remodelling
The remodelling of the vessel wall involves persistent modifications which may result from
several remodelling signals, such as (a) the wall shear stress (which mechanisms have been
previously discussed), (b) the circumferential wall stress (resulting from the stretch of the
smooth muscle layer) and (c) specific metabolic signals [19, 107]. As mentioned above, the
physiologic metabolic control of coronary blood flow mainly involves CO2 and ROS. In a
pathological setting (i.e. myocardial ischaemia) however, the metabolic control may involve
several mediators, such as oxygen, adenosine, prostaglandins, nitric oxide and protons [28].
In the presence of myocardial ischaemia, the decreased pO2 is detected by (a) the cardiomyo-
cytes triggering the production of adenosine (which promotes the VSMC hyperpolarization
through its receptors A2A and A2B) and NO, by (b) the endothelium, inducing the production
of prostaglandins and by (c) the VSMCs, where KATP and CaV channels are activated leading
to the hyperpolarization of these cells and to the vasodilation [28]. These remodelling signals
promote, on one hand, the increase in the luminal diameter and, on the other hand, the VSMC
plasticity and matrix remodelling, inducing the wall thickening [19, 108]. However, in the
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presence of certain factors, such as ageing, arterial hypertension and cardiomyopathies, these
mechanisms of adaptation may be impaired leading to pathogenic changes.
In addition to the functional changes, ageing may induce these structural modifications, namely
the proliferation of VSMCs and increase the inflammation status in the vascular wall, which
is linked to atherogenesis, leading to the remodelling of the vessel wall and to the decrease in
the luminal diameter [75].
Other situations may also contribute to the vascular remodelling, especially arterial hyper-
tension and cardiomyopathies. Previous studies have suggested that arterial hypertension may
promote the thickening of the smooth muscle layer, by stimulating the proliferation of VSMCs
and collagen fibres [3, 73].
Furthermore, cardiomyopathies (especially hypertrophic cardiomyopathy) may also contribute
to the vascular remodelling. According to Maron et al. [109], “cardiomyopathies are a hetero-
geneous group of diseases of the myocardium associated with mechanical and/or electrical
dysfunction that usually (but not invariably) exhibit inappropriate ventricular hypertrophy or
dilatation and are due to a variety of causes that frequently are genetic. Cardiomyopathies
either are confined to the heart or are part of generalized systemic disorders, often leading to
cardiovascular death or progressive heart failure-related disability”. The cardiomyopathies
are usually classified into primary and secondary, based on the American Heart Association
classification [109]. On the basis of the management of cardiomyopathy with a morphofunc-
tional phenotype, the European Society of Cardiology proposed in 2008 the classification of
cardiomyopathies into the hypertrophic (HCM), dilated (DCM), restrictive (RCM), arrhytmo-
genic right ventricular (ARVC) and unclassified varieties [110]. Each of these groups was
subdivided into familial or genetic and nonfamilial or nongenetic forms [110]. In 2014, another
classification was proposed by the World Heart Federation, involving a descriptive genotype-
phenotype nosology system, the MOGE(S) classification [111]. Vascular remodelling in
coronary arterioles has been previously associated with both HCM and DCM [73]. Similarly
to arterial hypertension, the remodelling of these vessels also involves the thickening of both
the smooth muscle layer and the intimal layer. These morphological changes may contribute
to the CMD associated with HCM, as patients with this cardiomyopathy showed a marked
decrease in vasodilator response in the endocardium, proportional to the degree of hypertro-
phy [3, 73]. Relatively to DCM, the degree of CMD may be considered an independent
prognostic factor for cardiac events [73, 112, 113].
4.2.2. Vascular rarefaction and perivascular fibrosis
The coronary microvascular function may also be influenced by modifications in the vascular
density, particularly by vascular rarefaction, that is the reduction in the number of microcir-
culatory vessels, which may also be recognized as hypotrophic remodelling [19]. The presence
of arterial hypertension and the extravascular compression, observed in aortic stenosis and
cardiomyopathies, induces vascular rarefaction leading to the reduction in the CFR. In addition
to the vascular rarefaction, both situations may also induce perivascular fibrosis promoting
structural modifications of the vessel wall [73, 114].
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4.2.3. Luminal obstruction
CMD may also be characterized by luminal obstruction originated from (a) obstructive CAD
or (b) iatrogenic microembolization [73].
According to the mechanisms underlying the associated CMD as well as the clinical findings,
the obstructive CAD may be divided into stable CAD, unstable CAD and AMI [73]. Changes in
the CFR were previously showed in patients with both stable CAD and acute coronary
syndromes.
In patients with stable CAD, the CMD distal to a coronary stenosis seems to be triggered
through two main pathways: (a) increased prearteriolar and arteriolar constriction, increasing
the blood flow resistance and decreasing the myocardial perfusion and (b) impaired prearter-
iolar dilation in the presence of increased myocardial oxygen demands [73]. Although in the
presence of coronary stenosis (for example during exercise), the transmural myocardial
perfusion tends to be redistributed, with an increase in the subendocardial perfusion. The
impairment of this mechanism in patients with stable CAD may lead to increased microvas-
cular vasoconstriction, which might promote a critical stenosis and thus capillary derecruit-
ment distal to the stenosis, ultimately contributing to CMD [73].
Similarly to stable CAD, unstable CAD (i.e. acute coronary syndromes without ST-segment
elevation) may also involve a CMD distal to a critical stenosis which might play a role in the
severity of the myocardial ischaemia. In addition to the mechanisms described for stable CAD,
this type of acute coronary syndromes also involves other mechanisms, such as thrombogen-
esis [73]. In fact, Marzilli et al. [115] suggested that the blockade of the platelet glycoprotein
IIb/IIIa receptor with abciximab might improve the microvascular function in patients with
unstable CAD. Moreover, the inflammation status may also come into play as suggested by
previous studies that showed a direct relation between CMD and the systemic levels of C-
reactive protein, a marker of inflammation independent of the cardiovascular risk factors [116,
117]. Both of these factors may contribute to the luminal obstruction observed in patients with
unstable CAD.
Luminal obstruction is a key characteristic of the AMI. Early after a myocardial infarction,
patients may present a marked reduction in the CFR that could significantly impair the
contractility of the myocardium in the infarction region [73]. In addition to the autonomic
dysfunction (previously explored), this impaired myocardial contractility might also be
reverted with α-blockers [73, 101]. Even after reperfusion procedures, the CMD involving
luminal obstruction in the stenotic and poststenotic areas may be responsible for the failure of
the reperfusion, situation usually known as “no-reflow” phenomenon. This phenomenon is
characterized by the lack of morphological and functional integrity in the microcirculation, in
spite of successful reperfusion procedures [12, 73, 118, 119] and is associated with clinically
significant decreased prognosis. The pathogenesis of the “no-reflow” phenomenon seems to
be multifactorial; thus, a classification has been previously proposed which divides this
phenomenon into (a) structural and (b) functional types. The structural type involves irrever-
sible changes in the wall of the microvessels, while the functional type includes morphologi-
cally intact yet functionally compromised microvessels. The functional changes include
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impairment of the endothelium-dependent vasodilation, autonomic nervous system dysfunc-
tion and extravascular compression due to interstitial oedema, among others [73, 120, 121].
Recently, O’Farrell et al. [12] proposed a key role of pericytes in the pathogenesis of this
phenomenon (Figure 8), suggesting that these cells irreversibly constrict the coronary micro-
circulation impeding the adequate reperfusion after AMI.
Figure 8. Role of pericytes in healthy and ischaemic microvessels: (a) normal blood flow in coronary arterioles and ca-
pillaries covered with pericytes; (b) in ischaemia, the pericytes may constrict the coronary microcirculation compro-
mising the coronary blood flow and leading to coronary microvascular dysfunction; (c) after reperfusion procedures,
the coronary microvascular dysfunction may block the re-establishment of the normal blood flow, situation usually
known as no-reflow phenomenon.
As previously mentioned, CMD may also be originated from iatrogenic microembolization after
coronary reperfusion procedures or coronary artery bypass grafting. During or after these
procedures, plaque rupture may occur thus releasing plaque content into the blood which in
turn might lead to luminal obstruction in the microcirculation [73].
4.2.4. Vascular wall infiltration
In addition to the previous explored structural changes, the infiltration of the vessel wall with
metabolic deposits may also be found. This infiltration is commonly found in infiltrative
diseases, such as Anderson-Fabry disease and other metabolic disorders. The Anderson-Fabry
disease involves a genetically linked (X chromosome) deficiency of lysosomal α-galactosidase
A, which leads to damages in several organs, namely the heart, through the deposition of
glycosphingolipid in cardiomyocytes and in the vascular wall [73]. In turn, this infiltration
promotes the hypertrophy and fibrosis of cardiomyocytes as well as CMD and perivascular
fibrosis [73]. In fact, Elliott et al. [122] demonstrated these patients present a marked decrease
in CFR, confirming the presence of CMD in the pathogenesis of the cardiomyopathy induced
by this disease.
5. Conclusions
This review provides an insight on the morphology, physiology and pathophysiology of
the cardiac microcirculation. As discussed, the heart is one of the most nutrient and oxygen
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demanding organs as this demand needs to be satisfied with an adequate vascularization
of the myocardium through an extensive macro- and microvascular network. Although
most of the cardiac diseases, such as the acute coronary syndrome, are commonly associat-
ed with the coronary macrocirculation (i.e. epicardial coronary arteries), the coronary mi-
crocirculation also seems to play a key role in the coronary pathophysiology. This role
involves both molecular and clinical aspects that should not be overlooked and that consti-
tute potential diagnostic and therapeutic targets, particularly important in the early patho-
genesis of these diseases.
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